Global Alzheimer’s Drugs Market: Overview
The key driving factor for the development of the global Alzheimer’s drug market is the increasing prevalence of the disease in the developed countries in the West. Numerous neurodegenerative disease have become increasingly prevalent in the countries such as the U.S. in the past few years, leading to a steady support from the government to develop drug for treatment. This has thus resulted in a highly favorable market conditions for the drug manufacturers of the Alzheimer’s disease and consequently driving the growth of the market in the region. Also there is an increasing awareness among people about treatment of the Alzheimer’s disease which has further contributed in the driving the growth of the global market.
The global Alzheimer’s drugs market stood at an overall valuation of US$3.6 bn in the years 2017. This valuation is estimated to reach to a figure of US$6.4 bn by the end of the given forecast period of 2017 to 2025. This growth in the overall market valuation is expected to be achieved at a steady growth CAGR of 7.5% over the course of the given forecast period.
Memantine Segment to Remain Key Class Type Owing to Limited Number of Drugs in Global Alzheimer’s Drug Market
The global market for Alzheimer’s drug can be segmented depending on the class type of the drug, distribution channel, and regional segmentation. Depending on the drug class, the Alzheimer’s drug market can be further segmented into memantine, cholinergic, and combined drugs. Memantine drug type dominated the global market for Alzheimer’s disease in the year 2016 owing to large scale expiry of patents of major products and a restricted number of drugs to treat Alzheimer’s disease. This segment of memantine drug is expected to dominate the market in the coming years of the forecast period. The cholinergic segment is also expected to contribute largely to the overall market share of the global market for Alzheimer’s drug and is projected to expand at a healthy growth rate over the forecast period because of the limited availability of the productive drug classes across the globe. The sales of combine drug class increased in the year 2016 when compared to its past record, and is expected to grow at a significant pace over the course of the given forecast period of 2017 to 2025.
North America Market to Reach an Overall Valuation of More than US$3 bn in Coming Years
Depending on the geography, the global Alzheimer’s drug market can be segmented into key regions such as Europe, Asia Pacific, North America, Latin America, and the Middle East and Africa. The regional market of North America accounted for the highest share in the global market for Alzheimer’s drugs in 2016 because of the large number of patients suffering from the Alzheimer’s disease and growing awareness among the regional population about the treatment of the disease. The North America market for Alzheimer’s drugs stood at overall valuation of US$1.7 bn in 2017 and is estimated to rise over US$3 bn by the end of the given forecast period in 2025.The regional market of Asia Pacific, on the other hand, is projected to show a strong growth CAGR of 8.6% during the give forecast period of 2017 to 2025.
Some of the key players in the global Alzheimer’s drug market include names such as H Lundbeck A/S, Ono Pharmaceutical, Johnson & Johnson, Eisai Co Ltd., and Daiichi Sankyo Company Limited among others.
Global Alzheimer’s Drugs Market: Overview
This report on the Alzheimer’s drugs market analyzes the current and future scenario of the global market. Increasing prevalence of Alzheimer’s, innovation in the development of new drugs, biomarker analysis and most promising molecules analysis, drug class sales during the forecast period.
Global Alzheimer’s Drugs Market: Research Methodology
The global Alzheimer’s drugs market report contain an elaborate executive summary, which includes following points such as market snapshot that provides information about various segments globally. It also comprise information and data analysis of the country’s market with respect to the segments based on drug class type, distribution channels and regions. A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section. Additionally, the section comprises PEST Analysis, Porters Five Forces Analysis and Pipeline Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of country and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global Alzheimer’s drug market.
Global Alzheimer’s Drugs Market: Segmentation
Based on drug class, the market has been segmented into four major drug class such as cholinergic, memantine, combined drugs, and others. The market segments have been analyzed based on available approved products, cost-effectiveness. All segments market size and forecast has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.
As per distribution channels, the global Alzheimer’s drugs market has been segmented into three segments including hospital pharmacy, retail pharmacy, and online sales. All market segmentations has been analyzed based on increasing demand for disease treatment. Increased patient hospitalization for the treatment of Alzheimer’s are driving the market share of hospital pharmacy segment. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also comprise the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.
Geographically, Alzheimer’s drugs market on the basis of region has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been presented for the period from 2015 to 2025. CAGR for all segments has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.
Global Alzheimer’s Drugs Market: Competitive Dynamics
The report also profiles major key players in the Alzheimer’s drugs market based on various attributes such as company overview, product portfolio, financial overview, business strategies, recent developments and company SWOT analysis. Major players operating in the Alzheimer’s drug market included in this report are Allergan plc, Novartis AG, Eisai Co Ltd, H Lundbeck A/S, Daiichi Sankyo Company Limited, Ono Pharmaceutical Co Ltd, Merz Holding GmbH & Co KG, and Johnson & Johnson.
Global Alzheimer’s Drugs Market is segmented as below:
Global Alzheimer’s Drug Market, by Drug Class
- Combined Drug
Global Alzheimer’s Drug Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Sales
Global Alzheimer’s Drug Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa